130 related articles for article (PubMed ID: 3296302)
41. Binding to prostaglandin (PG) receptors and activation of adenyl cyclase by 20-isopropylidene-PGS in rabbit platelet membranes.
Ushiyama S; Handa S; Yamazaki M
Prostaglandins; 1988 Oct; 36(4):477-89. PubMed ID: 2853419
[TBL] [Abstract][Full Text] [Related]
42. Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid.
Meanwell NA; Romine JL; Rosenfeld MJ; Martin SW; Trehan AK; Wright JJ; Malley MF; Gougoutas JZ; Brassard CL; Buchanan JO
J Med Chem; 1993 Nov; 36(24):3884-903. PubMed ID: 7504734
[TBL] [Abstract][Full Text] [Related]
43. Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species.
Narumiya S; Okuma M; Ushikubi F
Br J Pharmacol; 1986 Jun; 88(2):323-31. PubMed ID: 3730697
[TBL] [Abstract][Full Text] [Related]
44. The intrainfusion platelet rebound during and following PGE1-infusion is faster and more intensive than that with PGI2.
Sinzinger H; Reiter S
Prostaglandins Leukot Med; 1984 Mar; 13(3):281-8. PubMed ID: 6585847
[TBL] [Abstract][Full Text] [Related]
45. A scanning electron microscopic investigation of effects of prostacyclin on platelet retention in glass bead columns.
Ts'ao C; Krajewski D; Ng A
Scand J Haematol; 1982 Jan; 28(1):23-31. PubMed ID: 7041243
[TBL] [Abstract][Full Text] [Related]
46. The effect of 6-oxo-prostaglandin E1 on human platelet aggregation in whole blood in-vitro.
Wilsoncroft PS; Lofts FJ; Griffiths RJ; Moore PK
J Pharm Pharmacol; 1985 Feb; 37(2):139-41. PubMed ID: 2858551
[TBL] [Abstract][Full Text] [Related]
47. Human plasma transforms prostacyclin (PGI2) into a platelet antiaggregatory substance which contracts isolated bovine coronary arteries.
Gimeno MF; Sterin-Borda L; Borda ES; Lazzari MA; Gimeno AL
Prostaglandins; 1980 Jun; 19(6):907-16. PubMed ID: 6992238
[TBL] [Abstract][Full Text] [Related]
48. Enhancement of the antiaggregatory activity of prostacyclin by propranolol in human platelets.
Callahan KS; Johnson AR; Campbell WB
Circulation; 1985 Jun; 71(6):1237-46. PubMed ID: 2986877
[TBL] [Abstract][Full Text] [Related]
49. Nonprostanoid prostacyclin mimetics. 4. Derivatives of 2-[3-[2-(4,5-diphenyl-2-oxazolyl)ethyl]phenoxy]acetic acid substituted alpha to the oxazole ring.
Meanwell NA; Rosenfeld MJ; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Gamberdella M; Hartl KS; Zavoico GB
J Med Chem; 1993 Nov; 36(24):3871-83. PubMed ID: 8254619
[TBL] [Abstract][Full Text] [Related]
50. Desensitisation of human platelets against stimulation by thromboxane mimics--reduction in receptor capacity and loss of functional response.
Thierauch KH; Gabriel D; Prior G; Schillinger E
Biomed Biochim Acta; 1988; 47(10-11):S75-8. PubMed ID: 2470362
[TBL] [Abstract][Full Text] [Related]
51. Solubilization of prostacyclin membrane receptors from human platelets.
Tsai AL; Hsu MJ; Vijjeswarapu H; Wu KK
J Biol Chem; 1989 Jan; 264(1):61-7. PubMed ID: 2642482
[TBL] [Abstract][Full Text] [Related]
52. PGI2 and PGE1 induce morphological alterations in human platelets similar to those of the initial phase of activation.
Zilla P; Groscurth P; Varga G; Fischlein T; Fasol R
Exp Hematol; 1987 Aug; 15(7):741-9. PubMed ID: 3301381
[TBL] [Abstract][Full Text] [Related]
53. Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets.
Kobzar G; Mardla V; Järving I; Samel N
Cell Physiol Biochem; 2001; 11(5):279-84. PubMed ID: 11684817
[TBL] [Abstract][Full Text] [Related]
54. Stimulatory effects of vascular prostaglandins on the antiaggregatory activities of pentoxifylline acetylsalicylic acid combinations in vitro.
Weithmann KU; Just M; Schlotte V; Seiffge D
Vasa; 1989; 18(4):273-6. PubMed ID: 2514520
[TBL] [Abstract][Full Text] [Related]
55. Human prostacyclin platelet receptors and platelet lipid composition.
Modesti PA; Abbate R; Prisco D; Gensini GF
J Lipid Mediat; 1990; 2(6):309-15. PubMed ID: 2133274
[TBL] [Abstract][Full Text] [Related]
56. Prostaglandin releasing polymers - stability and efficacy.
McRea JC; Ebert CD; Kim SW
Trans Am Soc Artif Intern Organs; 1981; 27():511-6. PubMed ID: 7036503
[TBL] [Abstract][Full Text] [Related]
57. Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline.
Manrique RV; Manrique V
Angiology; 1987 Feb; 38(2 Pt 1):101-8. PubMed ID: 3030162
[TBL] [Abstract][Full Text] [Related]
58. The platelet rebound phenomenon during PGI2-infusion occurs at the receptor level.
Steurer G; Fitscha P; Sinzinger H
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):435-8. PubMed ID: 2465947
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of platelet aggregation and the stimulation of prostacyclin synthesis by insulin in humans.
Kahn NN; Bauman WA; Hatcher VB; Sinha AK
Am J Physiol; 1993 Dec; 265(6 Pt 2):H2160-7. PubMed ID: 8285255
[TBL] [Abstract][Full Text] [Related]
60. Critical evaluation of the in vivo selectivity between hypotensive and platelet antiaggregating actions of iloprost and prostacyclin in beagle dogs.
Hermán F; Hadházy P; Magyar K
Arch Int Pharmacodyn Ther; 1989; 300():281-91. PubMed ID: 2482710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
